Insulin receptor substrate 2 gene Gly1057Asp polymorphism is a risk factor for nonalcoholic fatty liver disease

Lab Med. 2024 Mar 7;55(2):215-219. doi: 10.1093/labmed/lmad066.

Abstract

Objective: Nonalcoholic fatty liver disease (NAFLD), which is an emerging global chronic liver disease, has a close association with insulin resistance. We aimed to determine whether the Gly1057Asp (rs1805097) polymorphism of the insulin receptor substrate 2 (IRS2) gene is associated with NAFLD.

Methods: Using the polymerase chain reaction-restriction fragment length polymorphism method, 135 patients with biopsy-proven NAFLD and 135 controls underwent IRS2 genotype analysis.

Results: Genotype and allele distributions of the IRS2 gene Gly1057Asp variant conformed to the Hardy-Weinberg equilibrium in both the case and control groups (P > .05). The Asp/Asp genotype of IRS2 gene Gly1057Asp polymorphism compared with Gly/Gly genotype was associated with a 2.1-fold increased risk for NAFLD after adjustment for confounding factors (P = .029; odds ratio = 2.10, 95% CI = 1.23-3.97).

Conclusion: Our findings revealed for the first time that the Gly1057Asp Asp/Asp genotype of the IRS2 gene is a marker of increased NAFLD susceptibility; however, studies in other populations are required to confirm the results.

Keywords: Gly1057Asp; IRS2; NAFLD; insulin receptor substrate 2; polymorphism; rs1805097.

MeSH terms

  • Case-Control Studies
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Insulin Receptor Substrate Proteins / genetics
  • Insulin Receptor Substrate Proteins / metabolism
  • Non-alcoholic Fatty Liver Disease* / genetics
  • Polymorphism, Genetic
  • Polymorphism, Single Nucleotide / genetics
  • Risk Factors

Substances

  • Insulin Receptor Substrate Proteins
  • IRS2 protein, human